ARTICLE | Company News
Incyte sales and marketing update
October 3, 2016 7:00 AM UTC
Incyte said that the National Comprehensive Cancer Network (NCCN) guidelines will include Jakafi ruxolitinib as a recommend treatment for myelofibrosis. The drug is a Janus kinase-1 (JAK-1) and JAK...